Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Type Condition

    Christiansburg, VA

    Search
    Christiansburg, VA
    Show Map
    Map View
    Christiansburg, VA
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      207 Clinical Trials near Christiansburg, VA

      Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Alisertib for Small Cell Lung Cancer

      Blacksburg, Virginia
      PUMA-ALI-4201 is a Phase 2 study evaluating alisertib monotherapy in patients with pathologically-confirmed small cell lung cancer (SCLC) following progression on or after treatment with one platinum-based chemotherapy and anti-PD-L1 immunotherapy agent. Up to one additional systemic anti-cancer therapy for SCLC is allowed, for a total of up to two prior lines of therapy. This study is intended to identify the biomarker-defined subgroup(s) that may benefit most from alisertib treatment and to evaluate the efficacy, safety, and pharmacokinetics of alisertib.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Prior AURKA Treatment, Others
      Must Not Be Taking:AURKA Inhibitors

      80 Participants Needed

      Early Aggressive vs Traditional Therapy for Multiple Sclerosis

      Christiansburg, Virginia
      FDA-approved multiple sclerosis (MS) disease-modifying therapies (DMTs) target the relapsing phase of MS but have minimal impact once the progressive phase has begun. It is unclear if, in the relapsing phase, there is an advantage of early aggressive therapy with respect to preventing long-term disability. The infectious risks and other complications associated with higher-efficacy treatments highlight the need to quantify their effectiveness in preventing disability. The TRaditional versus Early Aggressive Therapy for MS (TREAT-MS) trial is a pragmatic, randomized controlled trial that has two primary aims: 1) to evaluate, jointly and independently among patients deemed at higher risk vs. lower risk for disability accumulation, whether an "early aggressive" therapy approach, versus starting with a traditional, first-line therapy, influences the intermediate-term risk of disability, and 2) to evaluate if, among patients deemed at lower risk for disability who start on first-line MS therapies but experience breakthrough disease, those who switch to a higher-efficacy versus a new first-line therapy have different intermediate-term risk of disability.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased
      Age:18 - 60

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breast-feeding, Chemotherapy, Others
      Must Not Be Taking:Rituximab, Ocrelizumab, Teriflunomide, Others

      900 Participants Needed

      weSIPsmarter for Reducing Sugary Drinks

      Christiansburg, Virginia
      This study will include 12 rural Head Start programs, randomly assigned to one of two groups: weSIPsmarter vs. control. The main goal is to find out if weSIPsmarter helps reduce sugary drink consumption in preschool-aged children and their parents.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:2+

      Key Eligibility Criteria

      Disqualifiers:Prior Study Participation

      744 Participants Needed

      Sigvotatug Vedotin vs Docetaxel for Lung Cancer

      Blacksburg, Virginia
      This trial is testing a new drug, sigvotatug vedotin, against a standard drug, docetaxel, in patients with advanced lung cancer. The goal is to see if the new drug works better and to understand its side effects. Docetaxel (Taxotere) is a well-established chemotherapy agent used in the treatment of advanced non-small cell lung cancer (NSCLC), often after failure of first-line treatments.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Life Expectancy < 3 Months, Respiratory Conditions, Peripheral Neuropathy, Uncontrolled Diabetes, Others
      Must Be Taking:Platinum-based Chemotherapy, Anti-PD-(L)1

      703 Participants Needed

      Ivonescimab for Metastatic NSCLC

      Blacksburg, Virginia
      Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Small Cell Lung Cancer, CNS Metastases, Active Autoimmune, Others

      780 Participants Needed

      BMS-986489 vs Atezolizumab for Small Cell Lung Cancer

      Blacksburg, Virginia
      The Purpose of the Study is to Compare the Efficacy and Safety of BMS-986489 (Anti-fucosyl-GM1+ Nivolumab Fixed Dose Combination) in Combination with Carboplatin plus Etoposide to that of Atezolizumab with Carboplatin plus Etoposide as First-Line Therapy in Participants with Extensive-Stage Small Cell Lung Cancer.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Brain Metastases, Lung Diseases, Heart Diseases, Others

      530 Participants Needed

      Petosemtamab + Pembrolizumab for Head and Neck Cancer

      Blacksburg, Virginia
      This is a Phase 3 randomized, open-label study to evaluate the efficacy and safety of petosemtamab plus pembrolizumab vs pembrolizumab in first-line treatment of recurrent or metastatic PD-L1+ head and neck squamous cell carcinoma.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Issues, Others
      Must Be Taking:Pembrolizumab

      500 Participants Needed

      Petosemtamab for Head and Neck Cancer

      Blacksburg, Virginia
      This is a phase 3 open-label, randomized, controlled, multicenter study to compare petosemtamab vs investigator's choice monotherapy in HNSCC patients for the second- and third-line treatment of incurable metastatic/recurrent disease.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Cardiac Arrhythmia, Others
      Must Not Be Taking:Steroids

      500 Participants Needed

      Litifilimab for Cutaneous Lupus Erythematosus

      Blacksburg, Virginia
      This trial is testing BIIB059, a new medicine that targets specific immune cells, in patients with skin lupus who haven't responded to standard treatments. The goal is to see if it can reduce their skin symptoms by calming down these immune cells.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Active Skin Conditions, Mixed Connective Tissue Disease, Severe Lupus Nephritis, Active Neuropsychiatric SLE, Others
      Must Not Be Taking:Intralesional Corticosteroids, Immunosuppressives

      474 Participants Needed

      Tucatinib + Trastuzumab + Chemotherapy for Colorectal Cancer

      Blacksburg, Virginia
      This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also determine what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). Participants will be assigned randomly to the tucatinib group or standard of care group. The tucatinib group will get tucatinib, trastuzumab, and mFOLFOX6. The standard of care group will get either: * mFOLFOX6 alone, * mFOLFOX6 with bevacizumab, or * mFOLFOX6 with cetuximab mFOLFOX6 is a combination of multiple drugs. All of the drugs given in this study are used to treat this type of cancer.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Prior Systemic Therapy, Radiation, Neuropathy, Others
      Must Not Be Taking:Anti-HER2 Therapy

      400 Participants Needed

      Immunotherapy + Chemotherapy for Small Cell Lung Cancer

      Blacksburg, Virginia
      This trial tests a new combination of immunotherapy and chemotherapy for patients with advanced lung cancer. The treatment uses two drugs to help the immune system fight cancer, along with standard chemotherapy to kill cancer cells. Researchers hope this new approach will improve survival compared to existing treatments.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Immunodeficiency, Active CNS Metastases, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      460 Participants Needed

      Pembrolizumab SC vs IV for Lung Cancer

      Blacksburg, Virginia
      This trial is testing a new way to give the cancer drug pembrolizumab as an injection under the skin for people with advanced lung cancer. The goal is to see if this method works as well as the traditional IV method. The study will also check if it is safe and effective when used with standard chemotherapy.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Autoimmune Disease, HIV, Others
      Must Not Be Taking:Steroids, Immunosuppressants

      531 Participants Needed

      Osimertinib + Chemotherapy for Non-Small Cell Lung Cancer

      Blacksburg, Virginia
      The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO®) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due to mutations in the Deoxyribonucleic acid (DNA) which, if known, can help physicians decide the best treatment for their patients. One type of mutation can occur in the gene that produces a protein on the surface of cells called the Epidermal Growth Factor Receptor (EGFR). Osimertinib is an Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitor (TKI) that targets Epidermal Growth Factor Receptor (EGFR) mutations. Unfortunately, despite the benefit observed for patients treated with osimertinib, the vast majority of cancers are expected to develop resistance to the drug over time. The exact reasons why resistance develops are not fully understood but based upon clinical research it is hoped that combining osimertinib with another type of anti-cancer therapy known as chemotherapy will delay the onset of resistance and the worsening of a patient's cancer. In total the study aims to enroll approximately 586 patients, consisting of approximately 30 patients who will participate in a safety run-in component of the trial, and approximately 556 who will receive osimertinib alone or osimertinib in combination with chemotherapy in the main trial. In the main part of the trial there is a one in two chance of receiving osimertinib alone, and the treatment is decided at random by a computer. The study involves a Screening Period, Treatment Period, and Follow up Period. Whilst receiving study medication, it is expected patients will attend, on average, approximately 15 visits over the first 12 months and then approximately 4 visits per year afterwards. Each visit will last about 2 to 6 hours depending on the arrangement of medical assessments by the study centre.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Hypertension, Active Infection, Others
      Must Be Taking:EGFR-TKIs

      587 Participants Needed

      Tucatinib + T-DM1 for Breast Cancer

      Blacksburg, Virginia
      This study is being done to see if tucatinib with ado-trastuzumab emtansine (T-DM1) works better than T-DM1 alone to help patients who have a specific type of breast cancer called HER2 positive breast carcinoma. The breast cancer in this study is either metastatic (spread into other parts of the body) or cannot be removed completely with surgery. Patients in this study will be randomly assigned to get either tucatinib or placebo (a pill with no medicine). This is a blinded study, so neither patients nor their doctors will know whether a patient gets tucatinib or placebo. All patients in the study will get T-DM1, a drug that is often used to treat this cancer. Each treatment cycle lasts 21 days. Patients will swallow tucatinib pills or placebo pills two times every day. Patients will get T-DM1 injections from the study site staff on the first day of every cycle.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Untreated Brain Lesions, Leptomeningeal Disease, Others
      Must Be Taking:T-DM1

      466 Participants Needed

      Polatuzumab Vedotin + R-CHP vs R-CHOP for Diffuse Large B-Cell Lymphoma

      Blacksburg, Virginia
      This Phase III, randomized, double-blind, placebo-controlled study will compare the efficacy, safety, and pharmacokinetics of polatuzumab vedotin plus R-CHP versus R-CHOP in participants with previously untreated diffuse large B-cell lymphoma (DLBCL).
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Organ Transplant, Peripheral Neuropathy, Indolent Lymphoma, CNS Lymphoma, Others
      Must Not Be Taking:Corticosteroids, Cytotoxic Drugs, Monoclonal Antibodies

      1000 Participants Needed

      Ibrutinib + Rituximab for Follicular Lymphoma

      Blacksburg, Virginia
      The purpose of this study is to evaluate whether the addition of ibrutinib will result in prolongation of progression-free survival (PFS) when compared with rituximab alone in treatment naïve participants with follicular lymphoma.
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:60+

      Key Eligibility Criteria

      Disqualifiers:Transformed Lymphoma, Prior Treatment, CNS Lymphoma, Cardiovascular Disease, Others

      445 Participants Needed

      Mevrometostat + Enzalutamide for Prostate Cancer

      Blacksburg, Virginia
      This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Sex:Male

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, Brain Metastasis, Others
      Must Be Taking:Enzalutamide

      1000 Participants Needed

      Rilvegostomig + Bevacizumab for Liver Cancer

      Blacksburg, Virginia
      This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in combination with bevacizumab. This study will be conducted in participants with advanced HCC who are not amenable to curative therapy or locoregional therapy
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disorders, Primary Malignancy, Others
      Must Not Be Taking:Steroids, Immunosuppressants, Anticoagulants, Others

      1220 Participants Needed

      Immunotherapy + Chemotherapy for Non-Small Cell Lung Cancer

      Blacksburg, Virginia
      This trial is testing two new drugs, zimberelimab and domvanalimab, combined with chemotherapy for patients with advanced lung cancer that has spread and lacks specific genetic targets. These drugs help the immune system better recognize and attack cancer cells. The goal is to see if this combination improves survival compared to another drug, pembrolizumab, with chemotherapy.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Active Malignancy, Autoimmune Disease, CNS Metastases, Others
      Must Not Be Taking:Chronic Steroids, Immunosuppressants

      1069 Participants Needed

      EIK1001 + Pembrolizumab and Chemotherapy for Non-Small Cell Lung Cancer

      Blacksburg, Virginia
      This study is for patients with advanced/metastatic non-small cells lung cancer (NSCLC) who have not received any treatment through the vein for the advanced disease.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Small Cell Elements, Prior Malignancy, Active Infection, Others

      70 Participants Needed

      Why Other Patients Applied

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Trial

      Avutometinib + Sotorasib for Lung Cancer

      Blacksburg, Virginia
      This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Prior Malignancy, Brain Metastases, Heart Disease, Others
      Must Not Be Taking:CYP3A4 Inhibitors

      153 Participants Needed

      Combination Immunotherapies for Non-Small Cell Lung Cancer

      Blacksburg, Virginia
      This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Autoimmune Disease, HIV, Hepatitis, Others
      Must Not Be Taking:Corticosteroids, Immunosuppressives

      151 Participants Needed

      Tislelizumab + Investigational Agents for Head and Neck Cancer

      Blacksburg, Virginia
      This trial tests whether tislelizumab, alone or with other new treatments, can help patients with head and neck cancer that has come back or spread. Tislelizumab helps the immune system find and kill cancer cells by blocking a pathway that usually stops this process.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Nasopharynx Carcinoma, Active Malignancy, Others
      Must Not Be Taking:Anti-PD-1, Anti-PD-L1

      160 Participants Needed

      Divarasib + Pembrolizumab for Non-Small Cell Lung Cancer

      Blacksburg, Virginia
      This trial is testing a new drug called divarasib along with other cancer treatments. It focuses on people with advanced or metastatic non-small cell lung cancer. The study aims to see how divarasib moves through the body, its safety, and if it helps fight the cancer.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Squamous NSCLC, CNS Metastases, Others
      Must Not Be Taking:KRAS Inhibitors

      320 Participants Needed

      Screening Platform for Cancer Eligibility

      Blacksburg, Virginia
      The study objective is to determine the biomarker status of a participant's tumor tissue and use that status to determine eligibility for a linked Roche clinical trial.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Other Malignancies, Liver Disease, Cardiovascular Disease, Others

      15000 Participants Needed

      NGM707 + Pembrolizumab for Cancer

      Blacksburg, Virginia
      This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Others
      Must Not Be Taking:ILT2, ILT4, HLA-G

      179 Participants Needed

      Brentuximab Vedotin + Pembrolizumab for Advanced Cancers

      Blacksburg, Virginia
      This trial will find out whether brentuximab vedotin and pembrolizumab work together to treat different types of cancer. There will be several different types of cancer studied in the trial. The cancer must have spread to other parts of the body (metastatic). The study will also find out what side effects occur. A side effect is anything the treatment does besides treat cancer. This is a multi-cohort study.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastases, Carcinomatous Meningitis, Others
      Must Be Taking:PD-1 Inhibitors

      161 Participants Needed

      Sacituzumab Govitecan for Metastatic Cancer

      Blacksburg, Virginia
      This trial is testing a new medicine called sacituzumab govitecan-hziy in patients whose cancer has spread to other parts of their body. The medicine works by finding and attacking cancer cells with a powerful drug. Sacituzumab govitecan-hziy, approved in 2020, is used for treating metastatic triple-negative breast cancer.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Active CNS Metastases, Second Malignancy, Others
      Must Not Be Taking:Topoisomerase Inhibitors, Biologics

      227 Participants Needed

      Disitamab Vedotin for Breast Cancer

      Blacksburg, Virginia
      The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein). Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks. The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Metastasis, Recent Malignancy, Others
      Must Be Taking:Trastuzumab, Pertuzumab, Taxane, Others

      100 Participants Needed

      Cabozantinib + Atezolizumab for Advanced Cancers

      Blacksburg, Virginia
      This is a multicenter Phase 1b, open-label study to assess safety, tolerability, preliminary efficacy, and pharmacokinetics (PK) of cabozantinib taken in combination with atezolizumab in subjects with multiple tumor types, including advanced urothelial carcinoma (UC) (including bladder, renal pelvis, ureter, urethra), renal cell carcinoma (RCC), castration-resistant prostate cancer (CRPC), non-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), endometrial cancer (EC), hepatocellular cancer (HCC), gastric cancer/gastroesophageal junction cancer/lower esophageal cancer (GC/GEJC/LEC), colorectal cancer (CRC), head and neck (H\&N) cancer, and differentiated thyroid cancer (DTC). The study consists of two stages: in the Dose Escalation Stage, an appropriate recommended cabozantinib dose for the combination with standard dosing regimen of atezolizumab will be established; in the Expansion Stage, tumor-specific cohorts will be enrolled in order to further evaluate the safety and efficacy of the combination treatment in these tumor indications. Three exploratory single-agent cabozantinib (SAC) cohorts may also be enrolled with UC, NSCLC, or CRPC subjects. One exploratory single-agent atezolizumab (SAA) cohort may also be enrolled with CRPC subjects. Subjects enrolled in the SAC cohorts and SAA cohort may receive combination treatment with both cabozantinib and atezolizumab after they experience radiographic progressive disease per the Investigator per RECIST 1.1. Due to the nature of this study design, some tumor cohorts may complete enrollment earlier than others.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      914 Participants Needed

      12...7

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do clinical trials in Christiansburg, VA pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do clinical trials in Christiansburg, VA work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Christiansburg, VA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Christiansburg, VA is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Christiansburg, VA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a medical study in Christiansburg, VA?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest clinical trials in Christiansburg, VA?

      Most recently, we added Potato-Rich Diet for Type 2 Diabetes, Fruquintinib + FOLFIRI for Colorectal Cancer and Mevrometostat + Enzalutamide for Prostate Cancer to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Virginia

      Anxiety Clinical Trials in Virginia

      Schizophrenia Clinical Trials in Virginia

      ADHD Clinical Trials in Virginia

      Bipolar Disorder Clinical Trials in Virginia

      Multiple Sclerosis Clinical Trials in Virginia

      Autism Clinical Trials in Virginia

      Treatment Resistant Depression Clinical Trials in Virginia

      Borderline Personality Disorder Clinical Trials in Virginia

      Social Anxiety Disorder Clinical Trials in Virginia

      Parkinson's Disease Clinical Trials in Virginia

      Alzheimer's Disease Clinical Trials in Virginia

      By Location

      Clinical Trials near Richmond, VA

      Clinical Trials near Charlottesville, VA

      Clinical Trials near Norfolk, VA

      Clinical Trials near Fairfax, VA

      Clinical Trials near Roanoke, VA

      Clinical Trials near Falls Church, VA

      Clinical Trials near Virginia Beach, VA

      Clinical Trials near Newport News, VA

      Clinical Trials near Lynchburg, VA

      Clinical Trials near Chesapeake, VA

      Clinical Trials near Danville, VA

      Clinical Trials near Arlington, VA

      Other People Viewed

      By Subject

      203 Clinical Trials near Annandale, VA

      179 Clinical Trials near Gloucester, VA

      162 Clinical Trials near Richmond, VA

      209 Clinical Trials near Hampton, VA

      210 Clinical Trials near Roanoke, VA

      27 Multiple Sclerosis Trials near Richmond, VA

      17 Psoriasis Trials near Richmond, VA

      190 Clinical Trials near Gallipolis, OH

      179 Clinical Trials near Illinois

      Top Clinical Trials near Blacksburg, VA

      Top Clinical Trials near West Virginia

      Top Clinical Trials near Harrisonburg, VA

      By Trial

      Tucatinib + Doxil for Breast Cancer

      Tucatinib + Trastuzumab Emtansine for Brain Metastases

      Ivonescimab + FOLFOX for Colorectal Cancer

      Lethal Means Safety Counseling for Suicide Prevention

      Bemarituzumab + Chemotherapy for Stomach Cancer

      Chemotherapy + Nivolumab for Bladder Cancer

      ZZ06 for Solid Tumors

      DZD9008 vs Chemotherapy for Lung Cancer

      OMM for Parkinson's Disease

      Virtual Reality Treadmill Training for Traumatic Brain Injury

      Osteopathic Manipulative Therapy for Respiratory Diseases

      Osimertinib Rechallenge for Lung Cancer

      Related Searches

      Top Clinical Trials near Chula Vista, CA

      Top Clinical Trials near Clackamas, OR

      Top Clinical Trials near Clementon, NJ

      Top Clinical Trials near Clemmons, NC

      Nilotinib for Giant Cell Tumor

      Reminders for Shingles Vaccination

      Cognitive Training for Face Blindness

      Long-Term Ustekinumab for Pediatric Crohn's Disease

      CD123 Redirected T Cells for Leukemia

      Top Uterine-fibroids Clinical Trials

      Oral Tranexamic Acid for Joint Replacement Surgery

      Intravesical PPM Therapy for Bladder Cancer